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Development and validation of a model to predict the 10-year
risk of general practitioner-recorded COPD
Daniel Kotz1,2, Colin R Simpson2, Wolfgang Viechtbauer3, Onno CP van Schayck1,2 and Aziz Sheikh1,2,4
BACKGROUND: There is increasing interest in the earlier detection of, and intervention in, patients at highest risk of developing
chronic obstructive pulmonary disease (COPD).
AIMS: The objective of this research was to develop and validate a risk prediction model for general practitioner (GP)-recorded
diagnosis of COPD.
METHODS: We used data from 239 Scottish GP practices; two-thirds were randomly allocated to a derivation cohort and the other
third to a validation cohort. We included patients aged 35–74 years at the cohort entry date, and excluded patients with a recorded
diagnosis of COPD prior to the entry date and with missing data on smoking status.
RESULTS: There were 480,903 patients in the derivation cohort and 247,755 in the validation cohort. The incidence of COPD in the
total cohort was 5.53/1,000 patient-years of follow-up (95% conﬁdence interval (CI), 5.46–5.60). In the derivation cohort, the COPD
risk for ever- versus never-smokers was substantially higher in women (hazard ratio (HR) = 9.61, 95% CI, 8.92–10.34) than in men
(HR= 6.72, 95% CI, 6.19–7.30). Other risk factors for both sexes were level of deprivation and a previously recorded asthma
diagnosis. In the validation cohort, the model discriminated well between patients who did and those who did not develop COPD:
area under the receiver operating characteristics curve = 0.845 (95% CI, 0.840–0.850) for females and 0.832 (95% CI, 0.827–0.837)
for males.
CONCLUSIONS: We have developed and validated the ﬁrst risk prediction model for COPD, which has the major advantage of
being populated entirely by routinely collected data and consequently may be used for clinical practice.
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INTRODUCTION
Chronic obstructive pulmonary disease (COPD) is now one of the
leading causes of chronic morbidity and mortality worldwide.1 The
World Health Organization estimates that about 3.3 million people
die from COPD across the world each year (i.e., 6% of all deaths).2
Considering the high and still increasing prevalence of COPD
being seen in many parts of the world, this ﬁgure is expected to
rise substantially in the coming decades.3–5 In developed
countries, the health-care burden of COPD particularly affects
primary care where most patients with COPD are managed.6 Still,
even among primary care patients with known risk factors of the
disease, the rate of undiagnosed COPD is high.7 With an
increasing appreciation of the substantial morbidity and mortality
resulting from COPD, there is growing international interest in the
earlier detection of, and intervention in, patients with COPD; this
more proactive approach is, however, currently hampered by the
lack of clinically relevant, validated risk algorithms.
Smoking is the most important risk factor of COPD.1,8,9 Other
risk factors that have been identiﬁed as playing a role in the
aetiology of COPD include age, sex, socioeconomic status,
childhood asthma, body mass index, acute respiratory infections,
respiratory symptoms (such as cough and wheezing), occupa-
tional exposure to risk factors, exposure to biomass pollution
indoors (an important risk factor in developing countries), family
history of COPD, pulmonary tuberculosis, physical activity and
alpha-1 anti-trypsin deﬁciency.1,10 However, there is still a limited
understanding of these other risk factors, particularly with respect
to their independent contribution to COPD risk and if there are
differences in susceptibility between men and women.
There are currently no tools to predict the development of COPD
in individuals free of the disease. Most available tools are only able
to identify patients with already established, but undiagnosed,
COPD (see e.g., refs 11,12). There is then a pressing need for an
accurate and easy-to-use instrument that simultaneously takes
account of a range of risk factors and accurately identiﬁes
individuals at increased risk of developing COPD, thereby offering
the opportunity to target interventions in order to reduce
morbidity and mortality.13 The aim of this study was to develop
and validate a model for risk prediction of COPD using routinely
collected data from a large national primary care data set.
MATERIALS AND METHODS
The Primary Care Clinical Informatics Unit at the University of Aberdeen
collects data from General Practice Administration System for Scotland
practices and includes almost 5 million patient-years of individual patient-
level data.14,15 These practices have been shown to be representative of all
Scottish practices.16 Furthermore, the database has high completeness and
accuracy of morbidity data and recordings on patients’ tobacco use. Data
extracted from 239 general practitioner (GP) practices contributing to the
database were used in this analysis. Using the random sample function in
1Department of Family Medicine, CAPHRI School for Public Health and Primary Care, Maastricht University Medical Centre, Maastricht, The Netherlands; 2Allergy & Respiratory
Research Group, Centre for Population Health Sciences, The University of Edinburgh, Edinburgh, UK; 3Department of Psychiatry and Psychology, MHeNS School for Mental Health
and Neuroscience, Maastricht University, Maastricht, The Netherlands and 4Division of General Internal Medicine and Primary Care, Brigham and Women’s Hospital/Harvard
Medical School, Boston, MA, USA.
Correspondence: D Kotz (d.kotz@maastrichtuniversity.nl)
Received 18 November 2013; revised 10 January 2014; accepted 23 January 2014
www.nature.com/npjpcrm
All rights reserved 2055-1010/14
© 2014 Primary Care Respiratory Society UK/Macmillan Publishers Limited
SPSS Version 17.0 (SPSS, Chicago, IL, USA), 66% of practices (N=159) were
allocated to a derivation cohort and 34% (N= 80) to a validation cohort.
We deﬁned an open cohort of patients aged 35–74 at the start date
(1 April 1998), drawn from patients registered with the practices during the
period from 1 April 1998 to 1 April 2008. An entry date to the cohort was
deﬁned for each patient as the latest of the following dates: 35th birthday,
date of registration with the practice or start date of the cohort (1 April
1998). An exit date to the cohort was deﬁned for each patient as the
earliest of the following dates: date of ﬁrst recorded diagnosis of COPD,
date of deregistration with the practice, death or end date of the cohort
(1 April 2008). Patients were excluded if they had a recorded diagnosis of
COPD prior to the entry date or no recording of smoking status at any time.
The number of patient-years of follow-up was calculated as the difference
in years between each patient’s entry date and exit date into the cohort.
Coding of primary outcome and risk factors
The primary outcome was the ﬁrst recorded diagnosis of COPD during the
period between a patient’s entry date and exit date into the cohort. The
deﬁnition of COPD was based on codes from the Read Clinical
Classiﬁcation System, which was produced for clinicians in primary care
and is used by the majority of primary care electronic patient record
systems (read codes H3, H31 and below (excluding H3101, H31y0, H3122),
H32 and below, and H36 to H3z). For a complete list of Read codes used to
deﬁne outcome and risk factors see Supplementary Appendix I.
A range of potential risk factors for COPD, which have been described in
the literature and which were sufﬁciently recorded in the database, were
assessed. Age was categorised into 35–39, 40–44, 45–49, 50–54, 55–59,
60–64 and 65+ years. Smoking status was categorised into ‘ever-smoker’ or
‘never-smoker’. We deﬁned ‘ever-smokers’ as patients recorded as ‘smoker’
or ‘ex-smoker’ at any time, and ‘never-smokers’ as patients recorded as
‘non-smoker’ at any time and no codings as ‘smoker’ or ‘ex-smoker’ at any
other time. Asthma diagnosis was based on Read codes (see
Supplementary Appendix I) and regarded as a risk factor if it had been
recorded prior to the patient’s entry date into the cohort, with no
recording as a reference. Sex and socioeconomic status were regarded as
time invariant potential risk factors, with the latter being measured using
the Carstairs Index of Deprivation (coded 1= least deprived to 5 =most
deprived).17
There were too few data entries at baseline for the potential risk factors
acute respiratory infections, respiratory symptoms, asthma, physical
inactivity, ethnicity, occupational exposure to risk factors, family history
of respiratory disease, pulmonary tuberculosis, and prescription of adreno-
receptor agonists, bronchodilators, theophylline and inhaled corticoster-
oids, and hence these were discarded from the prediction analyses (all
variables were present in fewer than 3% of patients).
Statistical analyses
We performed an a priori test to determine whether an association
between COPD and the most important risk factor, smoking status, was
modiﬁed by sex by comparing a logistic regression model including
smoking status, sex and the other above-mentioned risk factors with a
model that in addition included the interaction term between smoking
status and sex. The step to the model including the interaction term was
statistically signiﬁcant (χ2 = 37.77, d.f. = 1, Po0.001). We therefore
performed all analyses for men and women separately.
The primary analysis consisted of the following steps, conducted
separately for men and women. In the derivation cohort, a multiple Cox
proportional hazard regression model was used to estimate the
coefﬁcients and hazard ratios (HRs) of the potential risk factors for the
primary outcome. On the basis of this model, a prognostic index (PI) was
calculated for each patient from the derivation cohort as PIder = ∑βiXi,
where βi is the regression coefﬁcient of the risk factor Xi from the Cox
model (this method was adapted from ref. 18). PIder ranged from 0 (lowest
risk) to 7.51 (highest risk) in males and from 0 to 7.48 in females and
was transformed into a variable with 10 categories based on the deciles of
PIder (the values for calculating PIder are presented in Supplementary
Appendix II). We then calculated the 10-year incidence rate of COPD per
interval in patients from the derivation cohort (1 = lowest incidence of
COPD; 10= highest), which we deﬁned as the 10-year predicted incidence
rate. PIval for patients was then calculated from the validation cohort using
the regression coefﬁcients from the derivation cohort. PIval was then again
transformed into a variable with 10 intervals, but using the same cutoff
points as in the derivation cohort. The 10-year observed incidence rate of
COPD per interval in patients from the validation cohort was then
determined. The accuracy of the risk prediction model in discriminating
between patients from the validation cohort who developed COPD versus
patients who did not was assessed by calculating the area under the
receiver operating characteristics curve (ROCAUC) for all values of PIval.
Finally, the prediction model was calibrated by plotting the predicted
10-year incidence of COPD against the observed incidence for each
interval on PIval in patients from the validation cohort.
In ancillary analyses, we deconstructed the prediction model and
calculated the ROCAUCs for models including only age, only smoking, and
only age and smoking using the same method as described above. The
purpose of this analysis was to compare the accuracy of the full prediction
model (including all risk factors) with models including only the most
important risk factors of COPD.
RESULTS
The total number of patients in the cohort was 728,658: 480,903
(66.0%) in the derivation cohort and 247,755 (34.0%) in the
validation cohort. The median follow-up duration was 7.92 years
(interquartile range = 3.76–10.00 years) and 7.88 years
(3.77–10.00), respectively (Table 1).
During the study period there were 27,088 incident cases of
COPD from 4.9 million patient-years of observation in the total
cohort (Table 1), giving a crude incidence rate for COPD of 5.53
per 1,000 patient-years (95% conﬁdence interval (CI), 5.46–5.60).
The mean age at COPD diagnosis was 65.43 (s.d. = 9.73) years, with
Table 1. Baseline characteristics of patients in the derivation and validation cohorts
Derivation cohort, N= 480,903 Validation cohort, N= 247,755 Total, N=728,658
Patient-years 3,229,285 1,669,471 4,898,756
Years follow-up, median (IQR) 7.92 (3.76–10.00) 7.88 (3.77–10.00) 7.92 (3.76–10.00)
COPD 3.81 (18,342) 3.53 (8,746) 3.7 (27,088)
Age, mean (s.d.) 50.5 (11.3) 50.7 (11.3) 50.6 (11.3)
Male sex 49.9 (235,552) 49.0 (121,306) 49.0 (356,858)
Ever smokers 55.6 (267,533) 54.5 (134,986) 55.2 (402,519)
Carstairs level of deprivation
1st Quintile (least deprived) 19.3 (92,946) 17.1 (42,330) 18.6 (135,276)
2nd Quintile 18.3 (87,957) 23.0 (57,035) 19.9 (144,992)
3rd Quintile 24.1 (115,976) 24.6 (61,014) 24.3 (176,990)
4th Quintile 23.0 (110,712) 20.0 (49,549) 22.0 (160,261)
5th Quintile (most deprived) 15.2 (73,312) 15.3 (37,827) 15.3 (111,139)
Prior asthma 3.2 (15,584) 3.4 (8,535) 3.3 (24,119)
Data are presented as column percentage (N), unless otherwise stated.
Abbreviations: COPD, chronic obstructive pulmonary disease; IQR, interquartile range.
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the risk of COPD being found to increase with age. This association
was stronger in males than in females (Table 2). In both sexes, the
risk of COPD increased with increasing socioeconomic deprivation
and in patients who had a previous recording of asthma (Table 2).
The most important modiﬁable risk factor was smoking. Com-
pared with never-smokers, the risk of COPD was substantially
higher in female smokers when compared with male smokers:
9.61 times higher in female ever-smokers (95% CI, 8.92–10.43) and
6.72 times higher in male ever-smokers (95% CI, 6.19–7.30).
The accuracy of the risk prediction model in discriminating
between patients who did and those who did not develop
COPD during the 10-year follow-up was ROCAUC = 0.845 (95% CI,
0.840–0.850) for females and ROCAUC = 0.832 (95% CI, 0.827–0.837)
for males (Table 3; the ROC curves are shown in Supplementary
Figure 1). The accuracy of the model was higher than that of the
deconstructed models that included only age, only smoking, or
only age and smoking (Table 3). Sensitivity and speciﬁcity values
for the various cutoffs on the model’s PI are presented in
Supplementary Appendix II.
Figure 1 shows the calibration plots for the full risk prediction
model including all risk factors in the validation data set,
separately for men and women. The model was well calibrated
except for the highest risk category, in which the incidence of
COPD was overestimated by the model.
Table 2. Multiple Cox regression models for the association between
risk factors and COPD in the derivation cohort, separately for females
(N= 245,351) and males (N= 235,552)
HRa,
females
95% CI
around HR
HRa,
males
95% CI
around HR
Lower Upper Lower Upper
Years of age
35–39 (reference) — — — — — —
40–44 2.05 1.75 2.41 2.06 1.72 2.46
45–49 3.71 3.19 4.31 3.87 3.29 4.56
50–54 5.49 4.75 6.34 6.02 5.14 7.04
55–59 8.15 7.07 9.40 9.66 8.28 11.27
60–64 10.52 9.13 12.11 14.01 12.04 16.32
65+ 25.75 22.46 29.52 31.89 27.48 37.01
Ever-smoker
(reference=never-
smoker)
9.61 8.92 10.34 6.72 6.19 7.30
Carstairs level of deprivation
1st Quintile (least
deprived:
reference)
— — — — — —
2nd Quintile 1.25 1.14 1.37 1.36 1.25 1.48
3rd Quintile 1.65 1.52 1.78 1.60 1.48 1.73
4th Quintile 1.95 1.80 2.11 1.91 1.77 2.06
5th Quintile (most
deprived)
2.58 2.39 2.79 2.52 2.34 2.73
Prior asthma
(reference=no
recording)
2.79 2.62 2.97 3.37 3.15 3.60
Abbreviations: CI, conﬁdence interval; COPD, chronic obstructive pulmon-
ary disease; HR, hazard ratio.
aHR of COPD diagnosis for a risk factor (or risk factor category) compared
with its reference, adjusted for all other risk factors.
Table 3. Accuracy of the full prediction model and deconstructed models in predicting the 10-year incidence of COPD in the validation cohort for
females (N= 126,449) and males (N= 121,306)
ROCAUC,
females
95% CI around ROCAUC ROCAUC,
males
95% CI around ROCAUC
Lower Upper Lower Upper
Model including only risk factor smoking 0.709 0.703 0.715 0.671 0.665 0.678
Model including only risk factor age 0.728 0.721 0.734 0.763 0.757 0.769
Model including risk factors age and smoking 0.829 0.824 0.834 0.817 0.812 0.822
Full model including all risk factors: age,
smoking, level of deprivation and prior asthma
0.845 0.840 0.850 0.832 0.827 0.837
Abbreviations: CI, conﬁdence interval; COPD, chronic obstructive pulmonary disease; ROCAUC, area under the receiver operating characteristics curve.
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Figure 1. Calibration plot of the full risk prediction model including
all risk factors showing the predicted and observed 10-year
incidence of chronic obstructive pulmonary disease (COPD) per risk
category in the validation cohort for females (upper) and males
(lower).
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DISCUSSION
Main ﬁndings
We have developed and validated the ﬁrst model for risk
prediction of incident cases of COPD using routinely collected
data from a very large national general practice database. In the
derivation cohort, the COPD risk was 9.6 times higher in female
ever-smokers compared with never-smokers and 6.7 times higher
in male ever-smokers compared with never-smokers. The risk of
COPD increased for both sexes with increasing level of deprivation
and in patients with a previous recording of asthma. In the
validation cohort, the model discriminated well between patients
who did and those who did not develop COPD.
Strengths and limitations of this study
An advantage of the approach followed in this study is the
inclusion of less well-established risk factors. All time variant risk
factors in our model were recorded by the GPs before the patients’
entry date into the cohort. We used a longitudinal design in which
we followed up patients for a median duration of 8 years.
Furthermore, we were able to assess the interaction between sex
and the most important risk factor, smoking, which has not been
possible before. However, only risk factors that are sufﬁciently
assessed and/or recorded in general practice could be considered.
Although we included the most important risk factors known from
the literature, other factors may have been overlooked, such as
physical inactivity as well as occupational exposure to dust,
chemical agents and fumes. Inclusion of such risk factors, in the
presence of sufﬁciently recorded data, may have increased
the accuracy of the model. Also, the use of routine data did not
allow us to calculate pack-years of smoking history, which would be
the desirable indicator of risk from tobacco exposure than our rather
crude categorization of ‘ever-smokers’ versus ‘never-smokers’.
We used a GP-recorded diagnosis of COPD to deﬁne our
primary outcome, but the diagnosis could not be formally veriﬁed
through linkage to individual lung function measures. As a
consequence, misclassiﬁcation of COPD (over- or under-diagnosis)
may have occurred in some cases. It would have been very useful
to validate the GPs’ diagnosis of COPD with individual patient
spirometric data, but, unfortunately, these data were not available
in our database. Generally speaking, however, the validity of the
GP-recorded diagnosis of COPD in Scottish primary care can be
considered accurate. Since the publication of the National Institute
for Health and Clinical Excellence guideline for the management
of COPD in 2004 and the introduction of the Quality Outcomes
Framework, which provides GP practices additional payment for
high levels of clinical care, the recording of spirometry values in
COPD patients has markedly increased.19 A recent study under-
taken in Scottish GP practices showed that 88% of COPD patients
had a recording of forced expiratory volume in 1s in the previous
15 months.20 Results from a Dutch study indicate that the validity
and quality of spirometry performed in general practice is
satisfactory compared with spirometry performed in a pulmonary
function laboratory.21 Furthermore, a Canadian study showed that
individuals with COPD can be accurately identiﬁed in health
administration data.22 Nevertheless, it should be noted that COPD
is a complex disease that consists of several clinical phenotypes,23
but these were not distinguished by our model.
Interpretation of ﬁndings in relation to previously published work
Our work is novel in its use of a longitudinal primary care database
to predict future COPD in a population of individuals registered
who have no previous recording of the disease. The incidence rate
of 5.53 per 1,000 patient-years was higher than that found in our
earlier analysis of English QResearch practices (2.0 per 1,000
patient-years); however, data from QResearch included the entire
population and the estimates are therefore likely to substantially
underestimate incidence in the age groups most at risk for
COPD.24 Our incidence rate was also higher than that found in a
Dutch study25 using a GP database (2.9 per 1,000 patient-years)
but comparable to that found in a Canadian study26 using
population-based health administrative data (5.9 per 1,000
person-years). Differences between studies in reported rates
may be explained by differences in source population, deﬁnition
of outcome and duration of follow-up.
As expected, smoking was found to be the most important
modiﬁable risk factor for COPD. The risk was substantially higher
in female smokers than in male smokers. This important ﬁnding
indicates that smoking is likely to lead to higher rates of newly
diagnosed COPD among women than in men. There is some
evidence from previous research that females who smoke are
more susceptible to developing COPD than men who smoke.27
Explanations for this phenomenon include gender differences in
which cigarette smoke is inhaled and metabolised, genetic
predisposition for smoking-related lung damage and differences
in airway anatomy.28,29 It may also be possible, however, that this
gender difference is a result of bias. If, for example, men are more
likely to underreport their smoking behaviour or are less likely to
be recorded as a smoker, there would be a higher misclassiﬁcation
rate among men, causing bias towards a smaller HR. Furthermore,
if some important but unmeasured risk factor would exist
primarily in men (e.g., occupational exposure to dust, chemicals
or fumes) the relative risk of another risk factor (smoking) would
be lower in men than in women.
We also found that increasing socioeconomic deprivation was a
risk factor for COPD diagnosis, independent of smoking status. The
association between COPD and socioeconomic status has been
found previously26,30 and is likely due to a number of exposures,
including environmental or occupational exposure to smoke or to
other pollutants.
Similar to our cohort, previous studies reported that patients
with physician-diagnosed asthma were at increased risk of
developing COPD.25,31 It has been hypothesised that asthma
and COPD share a common background32 and that airway
inﬂammation in those with increased airway hyperresponsiveness
may lead to lung remodelling with resulting airﬂow obstruction.
The model discriminated well between patients who did and
those who did not develop COPD during the 10 years of follow-up,
indicated by ROCAUCs of 0.85 for females and 0.83 for males with
very small CIs. These ﬁgures were higher than for the decon-
structed model including only age and smoking (ROCAUCs of 0.83
for females and 0.82 for males). Thus, inclusion of the risk factors,
level of deprivation and previous recording of asthma, increased
the accuracy of predicting future COPD over and above the most
important and well-known risk factors smoking and age. The
model’s calibration was also good, except for the highest risk
category in which the incidence of COPD was slightly over-
estimated by the model. This may have been the result of the very
high HRs in the oldest-age category (HR= 25.75 for females and
HR= 31.89 for males aged 65+ years relative to the 35–39 age
category).
Implications for future research, policy and practice
Our risk prediction model has the potential to be used in routine
clinical practice to identify those at highest risk and thereby offers
the opportunity for better and more efﬁcient targeting of
interventions aiming to reduce the risk of developing COPD, in
particular smoking cessation interventions. For this use, we have
developed a simple ‘COPD risk calculator’ (see Supplementary
Appendix III). Our model is therefore complementary to the various
existing risk models concerned with the early detection of patients
with existing, but still undiagnosed, COPD (see e.g., refs 11,12).
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Conclusions
In summary, we have developed and validated the ﬁrst risk
prediction model for the development of COPD, which has the
major advantage of being populated entirely by routinely
collected data held in electronic health records.
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